Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP-AMPK-mTOR-SREBP1 signaling pathway.
Liu G, Kuang S, Cao R, Wang J, Peng Q, Sun C.
Liu G, et al. Among authors: kuang s.
FASEB J. 2019 Sep;33(9):10089-10103. doi: 10.1096/fj.201802619RR. Epub 2019 Jun 14.
FASEB J. 2019.
PMID: 31199678
Taken together, our results suggest that sorafenib's anticancer activity in liver cancer cells is based on the inhibition of ATP production, SCD1 expression, and monounsaturated FA synthesis. ...To our knowledge, this is the first evidence that sorafenib disrupts lipogenes …
Taken together, our results suggest that sorafenib's anticancer activity in liver cancer cells is based on the inhibition of ATP prod …